Litigation Details for Baxalta Incorporated v. Genentech, Inc. (Fed. Cir. 2022)
✉ Email this page to a colleague
Baxalta Incorporated v. Genentech, Inc. (Fed. Cir. 2022)
| Docket | ⤷ Subscribe | Date Filed | 2022-02-10 |
| Court | Court of Appeals for the Federal Circuit | Date Terminated | |
| Cause | Assigned To | ||
| Jury Demand | Referred To | ||
| Patents | 8,829,165; 8,859,741 | ||
| Link to Docket | External link to docket | ||
Biologic Drugs cited in Baxalta Incorporated v. Genentech, Inc.
The biologic drug covered by the patents cited in this case is ⤷ Subscribe .
Details for Baxalta Incorporated v. Genentech, Inc. (Fed. Cir. 2022)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2023-05-30 | 47 | company’s 2011 patent. See U. S. Patent No. 8,829,165 (Sept. 9, 2014); U. S. Patent No. 8,859,741 (… F.3d 1080 at 1083. 223 Ex. TT, U.S. Patent No. 8,829,165 at 77:20-81:34 (Example 3). 224 Garcia…that the patents were invalid under §112 of the Patent Act. That provision requires a patent applicant…opines that “[t]he ‘590 Patent has even less support and guidance than other patents that have been found… Amgen patents, and “[t]he disclosure supporting the functional limitations in Amgen’s patent claims | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
